Burlington Stores, Oracle, Nutanix Are Among Top 10 Large Cap Losers Last Week (Nov. 24-Nov. 28): Are the Others in Your Portfolio?

A basket of large-cap names underperformed last week led by Nutanix (-18.06%) after worse-than-expected Q1 sales, reduced Q2 guidance and lowered 2026 sales outlook that prompted analyst cuts; Burlington (-11.09%) reported mixed Q3 results and a notable drop in post–back-to-school store traffic. Other decliners include Zscaler (-9.53%) and Veeva (-3.79%) following Q1 results and downward price-target revisions, Oracle (-2.58%) and Deere (-2.75%) after analyst cuts and an announced ~$1.2 billion pre-tax annual tariff hit, while BeOne Medicines slipped modestly despite receiving FDA priority review for Sonrotoclax. These developments suggest near-term downside pressure on affected stocks and warrant reassessment of sector-specific exposures (cloud/software, retail, industrials and biotech) rather than broad-market implications.

Analysis

Market Structure: Guidance-driven hits at NTNX, ZS and BURL signal a near-term pullback in discretionary enterprise spend and retail traffic; incumbents with sticky recurring revenue (VEEV, ORCL cloud segments) are relatively insulated. Expect weaker pricing power for point-security vendors and mid-cycle capex pause in enterprise hardware/software for 1–3 quarters, benefiting hyperscalers (AWS/Azure) via share gains but pressuring smaller software vendors' top-line growth by 10–30% on miss continuity.

Risk Assessment: Tail risks include a larger-than-expected enterprise spending contraction (15–25% YoY revenue re-steering) and a cascade of analyst downgrades that widens equity-swap funding costs; FDA binary events (ONC) and DE’s $1.2B tariff exposure are 3–12 month idiosyncratic shocks that could drive >20% moves. Hidden dependencies: OEM supply-chain delays and Chinese/EM tariff policy could amplify DE and ACM margin hits and trigger credit-spread widening in corporate bonds over 6–12 months.

Trade Implications: Short-duration trades favor downside protection on NTNX (put spreads 3–6 months) and long ONC call spreads into the FDA decision window (~6 months). Construct pair trades: long VEEV vs short ZS for 3–9 months to capture relative resilience; reduce BURL exposure and reallocate into subscription software and defensive consumer staples for H2 2025.

Contrarian Angles: The market may be over-discounting long-term ARR resilience at NTNX/ZS; selectively buy NTNX convertible or secured debt on >30% pullback with 12–18 month horizon. Conversely, ORCL’s price-target cut may understate its free-cash-flow conversion; consider staged 6–12 month option-backed accumulation if shares fall >15% from current levels.

Key Decisions for Investors

• Establish a 1–2% portfolio short on NTNX using a 3–6 month put spread (buy 15% OTM, sell 30% OTM) to cap capital at risk; target gross return of 20–40% if guidance downgrades continue, stop-loss at 12% adverse move.
• Implement a relative-value pair: long VEEV (2–3% notional) and short ZS (2–3% notional) for 3–9 months to capture ARR stability vs guidance-driven weakness; trim if VEEV underperforms by >12% or ZS outperforms by >15%.
• Buy a 6-month call spread on ONC sized to 0.5–1% portfolio risk (ATM to +30% strike) ahead of the FDA priority-review action (~within 6 months); target 2–4x premium on approval, hedge with a 25% premium stop.
• Reduce exposure to BURL by 50% (or cut to <1% portfolio) and redeploy into defensive names or high-quality subscription software (e.g., increase VEEV allocation) over the next 4–12 weeks; hedge industrial exposure (DE/ACM) with 3-month puts if tariffs widen or lead indicators weaken.